Clinical Advances in Hematology & Oncology最新文献_第3页

Active treatment in high-risk, early-stage CLL or SLL. 积极治疗高危、早期CLL或SLL。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-06-01

Deborah M Stephens

引用次数: 0

Practical approach to MRD testing in breast cancer: Q&A. 乳腺癌MRD检测的实用方法：问答。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-06-01

Jason A Mouabbi, Marla D Lipsyc-Sharf, Fengting Yan

引用次数: 0

MRD testing across the continuum of care. 在整个护理过程中进行MRD测试。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-06-01

Jason A Mouabbi

引用次数: 0

The development of second-generation KRAS inhibitors. 第二代KRAS抑制剂的开发。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-06-01

Eileen M O'Reilly

引用次数: 0

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions. PARP抑制剂在乳腺癌、卵巢癌和前列腺癌中的临床应用：目前的见解和未来的方向。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-06-01

Laura M Linville, Jenna V Canzoniero, Catherine H Marshall, Deborah K Armstrong, Mark C Markowski, Michael A Carducci

{"title":"Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.","authors":"Laura M Linville, Jenna V Canzoniero, Catherine H Marshall, Deborah K Armstrong, Mark C Markowski, Michael A Carducci","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as an important therapeutic option for patients with homologous recombination repair (HRR)-deficient cancers, especially those with BRCA1/2 mutations. Since the initial US Food Administration approval of olaparib in 2014, PARP inhibitors have shown efficacy across ovarian, breast, and prostate cancers, although differences in trial design and biomarker strategies have resulted in tumor-specific indications. Homologous recombination deficiency (HRD) arises from germline or somatic mutations in HRR genes or from epigenetic inactivation, and it can be assessed through genomic \"scars\" such as loss of heterozygosity and mutational signatures. Although BRCA1/2 alterations confer the strongest sensitivity to PARP inhibitors, non-BRCA HRR gene mutations demonstrate heterogeneous responses, highlighting the need for more precise HRD assessment, including the role of biallelic vs monoallelic inactivation. Despite initial success, both primary and acquired resistance-through reversion mutations, replication fork stabilization, and therapy-induced clonal hematopoiesis-limit the durability of the response to PARP inhibition. Ongoing studies are evaluating rational combinations targeting complementary DNA damage response pathways (ATR/CHK1/WEE1, PI3K/AKT) and integrating immunotherapy or hormonal agents to extend benefit. Moving forward, harmonizing HRD testing across tumor types, accounting for germline, somatic, and liquid biopsy-derived alterations, and refining patient selection will be essential to maximize therapeutic efficacy and safely expand PARP inhibitor use beyond canonical BRCA-mutated cancers.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 4","pages":"197-206"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148229101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting BRAF V600E mutations in metastatic colorectal cancer. 靶向BRAF V600E突变的转移性结直肠癌

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-06-01

Scott Kopetz

引用次数: 0

Targeting human kallikrein 2 in prostate cancer. 靶向人小肽激酶2治疗前列腺癌。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-06-01

Mark N Stein

引用次数: 0

Addressing late detection of systemic relapse, the clinical blind spot. 解决晚期发现全身复发的临床盲点。